The current stock price of KRMD is 6.23 USD. In the past month the price increased by 7.41%. In the past year, price increased by 58.12%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.02 | 217.08B | ||
| ISRG | INTUITIVE SURGICAL INC | 67.11 | 204.83B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.56 | 142.40B | ||
| SYK | STRYKER CORP | 26.9 | 135.46B | ||
| BDX | BECTON DICKINSON AND CO | 13.62 | 56.04B | ||
| IDXX | IDEXX LABORATORIES INC | 54.6 | 54.98B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.79 | 50.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.22 | 38.09B | ||
| RMD | RESMED INC | 24.72 | 35.73B | ||
| DXCM | DEXCOM INC | 36.33 | 26.35B | ||
| PODD | INSULET CORP | 63.16 | 20.31B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.22 | 17.99B |
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Mahwah, New Jersey and currently employs 80 full-time employees. The firm is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The firm is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
KORU MEDICAL SYSTEMS INC
100 Corporate Drive
Mahwah NEW JERSEY 10918 US
CEO: James M. Beck
Employees: 80
Phone: 18454692042
KORU Medical Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. The company is headquartered in Mahwah, New Jersey and currently employs 80 full-time employees. The firm is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The firm is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
The current stock price of KRMD is 6.23 USD. The price decreased by -3.86% in the last trading session.
KRMD does not pay a dividend.
KRMD has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
The Revenue of KORU MEDICAL SYSTEMS INC (KRMD) is expected to grow by 20.76% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
KORU MEDICAL SYSTEMS INC (KRMD) currently has 80 employees.
The outstanding short interest for KORU MEDICAL SYSTEMS INC (KRMD) is 2.29% of its float.
ChartMill assigns a technical rating of 10 / 10 to KRMD. When comparing the yearly performance of all stocks, KRMD is one of the better performing stocks in the market, outperforming 94.24% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to KRMD. KRMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months KRMD reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS increased by 30% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.7% | ||
| ROE | -22.55% | ||
| Debt/Equity | 0.03 |
11 analysts have analysed KRMD and the average price target is 5.97 USD. This implies a price decrease of -4.22% is expected in the next year compared to the current price of 6.23.
For the next year, analysts expect an EPS growth of 28.6% and a revenue growth 20.76% for KRMD